NCT05387499 is a Phase 1 clinical trial of NP-011 (Single Ascending Dose Phase) in Myocardial Infarction, sponsored by Nexel Co., Ltd..

Who is sponsoring NCT05387499?

NCT05387499 is sponsored by Nexel Co., Ltd..

What drugs are being tested in NCT05387499?

Interventions in NCT05387499: NP-011 (Single Ascending Dose Phase), NP-011 (Multiple Ascending Dose Phase), NP-011 (Placebo).

What condition does NCT05387499 study?

NCT05387499 studies Myocardial Infarction.

Is NCT05387499 still recruiting?

NCT05387499 is currently completed. Last updated 3 August 2023.

Last reviewed 2023-08-03 · How we verify

NCT05387499

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of NP-011 in Healthy Volunteers

Completed Phase 1 Last updated 3 August 2023

What this trial tests

Phase 1 trial testing NP-011 (Single Ascending Dose Phase) in Myocardial Infarction in 64 participants. Completed in 26 May 2023.

Timeline

10 June 2022

Primary endpoint
7 March 2023

26 May 2023

Quick facts

Lead sponsor	Nexel Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	64
Start date	10 June 2022
Primary completion	7 March 2023
Estimated completion	26 May 2023
Sites	1 location across Australia

Drugs / interventions tested

NP-011 (Single Ascending Dose Phase) — full drug profile →
NP-011 (Multiple Ascending Dose Phase) — full drug profile →
NP-011 (Placebo)

Conditions studied

Myocardial Infarction — all drugs for Myocardial Infarction →

Sponsor

Nexel Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetic of NP-011 in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05387499 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nexel Co., Ltd.
Last refreshed: 3 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05387499.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing